Shares of IsoRay, Inc. (NASDAQ:ISR) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12 month consensus price target of $1.13 for the company and are forecasting that the company will post ($0.01) EPS for the current quarter, according to Zacks. Zacks has also given IsoRay an industry rank of 24 out of 254 based on the ratings given to its competitors.

Separately, HC Wainwright reiterated a “buy” rating on shares of IsoRay in a research note on Wednesday, February 12th.

Shares of NASDAQ ISR traded up $0.03 during midday trading on Friday, hitting $0.73. 7,108 shares of the company traded hands, compared to its average volume of 576,374. IsoRay has a 12-month low of $0.29 and a 12-month high of $1.06. The firm has a 50-day moving average of $0.64.

IsoRay (NASDAQ:ISR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.01) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.01). The business had revenue of $2.88 million during the quarter, compared to analysts’ expectations of $2.76 million.

About IsoRay

IsoRay, Inc, through its subsidiary, IsoRay Medical, Inc, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

Further Reading: What is meant by holder of record?

Get a free copy of the Zacks research report on IsoRay (ISR)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with's FREE daily email newsletter.